USPSTF Issues PrEP Recommendations for HIV PreventionJune 13, 2019
The U.S. Preventive Services Task Force (USPSTF) released a final recommendation statement and evidence summary for the use of preexposure prophylaxis (PrEP) with effective antiretroviral therapy for individuals who are at high risk of human immunodeficiency virus (HIV) acquisition.
According to the Task Force recommendations, clinicians should consider PrEP for the following individuals:
Men who have sex with men and have a serodiscordant sex partner, inconsistent use of condoms, or a diagnosis of syphilis, gonorrhea, or chlamydia within the past 6 months.
Heterosexually active women and men who have a serodiscordant sex partner, inconsistent use of condoms, or a diagnosis of a syphilis or gonorrhea within the past 6 months.
Individuals who inject drugs and use shared injection equipment or are at risk of sexual HIV acquisition as outlined above.
The USPSTF recommendation is a Grade A recommendation; there is high certainty that the net benefit is substantial, and providers should offer or provide this service. Before prescribing PrEP, clinicians should exclude persons with acute or chronic HIV infection via medical history and HIV testing.
Preexposure prophylaxis for the prevention of HIV infection: U.S. Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(22):2203-2213. Available at: click here. Accessed June 12, 2019.